Autoimmune drugs Market Size - Growth by 2031
The Autoimmune drugs Market is expected to register a CAGR of 5.5% from 2023 to 2031, with a market size expanding from US$ XX million in 2023 to US$ XX Million by 2031.
The report is divided into two sections: Product (B cell Inhibitors, T cell inhibitors, Tumor Necrosis Factor inhibitors, Interleukin inhibitors, immunosuppressant, Beta interferon, Insulin) and Application (Grave Diseases, Rheumatoid Arthritis, Hashimotos Thyroiditis, Vitiligo, Type 1 Diabetes, Pernicious Anemia). The global analysis is broken down at the regional level and major countries. The market evaluation is presented in US$ for the above segmental analysis.
Purpose of the ReportThe report Autoimmune drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Autoimmune drugs Market Segmentation
Product- B cell Inhibitors
- T cell inhibitors
- Tumor Necrosis Factor inhibitors
- Interleukin inhibitors
- immunosuppressant
- Beta interferon
- Insulin
- Grave Diseases
- Rheumatoid Arthritis
- Hashimotos Thyroiditis
- Vitiligo
- Type 1 Diabetes
- Pernicious Anemia
Strategic Insights
Autoimmune drugs Market Growth Drivers- Rising Prevalence of Autoimmune Diseases: The increasing incidence of autoimmune disorders like rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease due to factors like aging populations and changing lifestyles is a key driver.
- Technological Advancements: Innovations in drug discovery and development, such as biosimilars, targeted therapies, and personalized medicine approaches, are leading to more effective and safer treatments.
- Increased R&D Investments: Significant investments from both pharmaceutical companies and government agencies in research and development of novel autoimmune therapies are fueling market growth.
- Focus on Precision Medicine: Tailoring treatments to individual patients based on their genetic makeup and disease characteristics will become increasingly important.
- Rise of Biologics: Biologics, such as monoclonal antibodies and fusion proteins, are expected to dominate the market due to their high efficacy and specificity.
- Growing Importance of Biosimilars: The emergence of biosimilars will increase competition and potentially lower treatment costs, making therapies more accessible.
- Development of Novel Therapies: There remains a significant unmet medical need for many autoimmune diseases, creating opportunities for the development of novel therapies with improved efficacy and safety profiles.
- Expansion into Emerging Markets: The growing prevalence of autoimmune diseases in developing countries presents significant market opportunities for pharmaceutical companies.
- Personalized Medicine Approaches: Developing and implementing personalized medicine approaches can improve treatment outcomes and potentially reduce healthcare costs.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Autoimmune drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Autoimmune drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Autoimmune drugs Market is expected to grow at a CAGR of 5.5% between 2023-2031
The driving factors impacting the Autoimmune drugs Market are: Rising Prevalence of Autoimmune Diseases, Technological Advancements and Increased R&D Investments
The future trends of the Autoimmune drugs Market are: Focus on Precision Medicine, Rise of Biologics and Growing Importance of Biosimilars
The leading players of the market are: Abbott Laboratories, Active Biotech, AstraZeneca, GlaxoSmithKline, Johnson & Johnson Ltd, Lupin Limited, Eli Lilly and Company, Zydus, Bristol-Myers Squibb, AutoImmune Inc
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3-5 company profiles and country-specific analysis of 3-5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Autoimmune Drugs Market - By Product
1.3.2 Autoimmune Drugs Market - By Application
1.3.3 Autoimmune Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEWAYS
3. RESEARCH METHODOLOGY
4. AUTOIMMUNE DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. AUTOIMMUNE DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS, RESTRAINTS & EXPECTED INFLUENCE OF COVID-19 PANDEMIC
6. AUTOIMMUNE DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. AUTOIMMUNE DRUGS - GLOBAL MARKET OVERVIEW
6.2. AUTOIMMUNE DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. AUTOIMMUNE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. B CELL INHIBITORS
7.3.1. Overview
7.3.2. B cell Inhibitors Market Forecast and Analysis
7.4. T CELL INHIBITORS
7.4.1. Overview
7.4.2. T cell inhibitors Market Forecast and Analysis
7.5. TUMOR NECROSIS FACTOR INHIBITORS
7.5.1. Overview
7.5.2. Tumor Necrosis Factor inhibitors Market Forecast and Analysis
7.6. INTERLEUKIN INHIBITORS
7.6.1. Overview
7.6.2. Interleukin inhibitors Market Forecast and Analysis
7.7. IMMUNOSUPPRESSANT
7.7.1. Overview
7.7.2. immunosuppressant Market Forecast and Analysis
7.8. BETA INTERFERON
7.8.1. Overview
7.8.2. Beta interferon Market Forecast and Analysis
7.9. INSULIN
7.9.1. Overview
7.9.2. Insulin Market Forecast and Analysis
7.10. OTHERS
7.10.1. Overview
7.10.2. others Market Forecast and Analysis
8. AUTOIMMUNE DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. GRAVE DISEASES
8.3.1. Overview
8.3.2. Grave Diseases Market Forecast and Analysis
8.4. RHEUMATOID ARTHRITIS
8.4.1. Overview
8.4.2. Rheumatoid Arthritis Market Forecast and Analysis
8.5. HASHIMOTOS THYROIDITIS
8.5.1. Overview
8.5.2. Hashimotos Thyroiditis Market Forecast and Analysis
8.6. VITILIGO
8.6.1. Overview
8.6.2. Vitiligo Market Forecast and Analysis
8.7. TYPE 1 DIABETES
8.7.1. Overview
8.7.2. Type 1 Diabetes Market Forecast and Analysis
8.8. PERNICIOUS ANEMIA
8.8.1. Overview
8.8.2. Pernicious Anemia Market Forecast and Analysis
8.9. OTHERS
8.9.1. Overview
8.9.2. Others Market Forecast and Analysis
9. AUTOIMMUNE DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Autoimmune Drugs Market Overview
9.1.2 North America Autoimmune Drugs Market Forecasts and Analysis
9.1.3 North America Autoimmune Drugs Market Forecasts and Analysis - By Product
9.1.4 North America Autoimmune Drugs Market Forecasts and Analysis - By Application
9.1.5 North America Autoimmune Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Autoimmune Drugs Market
9.1.5.1.1 United States Autoimmune Drugs Market by Product
9.1.5.1.2 United States Autoimmune Drugs Market by Application
9.1.5.2 Canada Autoimmune Drugs Market
9.1.5.2.1 Canada Autoimmune Drugs Market by Product
9.1.5.2.2 Canada Autoimmune Drugs Market by Application
9.1.5.3 Mexico Autoimmune Drugs Market
9.1.5.3.1 Mexico Autoimmune Drugs Market by Product
9.1.5.3.2 Mexico Autoimmune Drugs Market by Application
9.1.5.4 US Autoimmune Drugs Market
9.1.5.4.1 US Autoimmune Drugs Market by Product
9.1.5.4.2 US Autoimmune Drugs Market by Application
9.2. EUROPE
9.2.1 Europe Autoimmune Drugs Market Overview
9.2.2 Europe Autoimmune Drugs Market Forecasts and Analysis
9.2.3 Europe Autoimmune Drugs Market Forecasts and Analysis - By Product
9.2.4 Europe Autoimmune Drugs Market Forecasts and Analysis - By Application
9.2.5 Europe Autoimmune Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Autoimmune Drugs Market
9.2.5.1.1 Germany Autoimmune Drugs Market by Product
9.2.5.1.2 Germany Autoimmune Drugs Market by Application
9.2.5.2 France Autoimmune Drugs Market
9.2.5.2.1 France Autoimmune Drugs Market by Product
9.2.5.2.2 France Autoimmune Drugs Market by Application
9.2.5.3 Italy Autoimmune Drugs Market
9.2.5.3.1 Italy Autoimmune Drugs Market by Product
9.2.5.3.2 Italy Autoimmune Drugs Market by Application
9.2.5.4 Spain Autoimmune Drugs Market
9.2.5.4.1 Spain Autoimmune Drugs Market by Product
9.2.5.4.2 Spain Autoimmune Drugs Market by Application
9.2.5.5 United Kingdom Autoimmune Drugs Market
9.2.5.5.1 United Kingdom Autoimmune Drugs Market by Product
9.2.5.5.2 United Kingdom Autoimmune Drugs Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Autoimmune Drugs Market Overview
9.3.2 Asia-Pacific Autoimmune Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Autoimmune Drugs Market Forecasts and Analysis - By Product
9.3.4 Asia-Pacific Autoimmune Drugs Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Autoimmune Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Autoimmune Drugs Market
9.3.5.1.1 Australia Autoimmune Drugs Market by Product
9.3.5.1.2 Australia Autoimmune Drugs Market by Application
9.3.5.2 China Autoimmune Drugs Market
9.3.5.2.1 China Autoimmune Drugs Market by Product
9.3.5.2.2 China Autoimmune Drugs Market by Application
9.3.5.3 India Autoimmune Drugs Market
9.3.5.3.1 India Autoimmune Drugs Market by Product
9.3.5.3.2 India Autoimmune Drugs Market by Application
9.3.5.4 Japan Autoimmune Drugs Market
9.3.5.4.1 Japan Autoimmune Drugs Market by Product
9.3.5.4.2 Japan Autoimmune Drugs Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Autoimmune Drugs Market Overview
9.4.2 Middle East and Africa Autoimmune Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Autoimmune Drugs Market Forecasts and Analysis - By Product
9.4.4 Middle East and Africa Autoimmune Drugs Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Autoimmune Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Autoimmune Drugs Market
9.4.5.1.1 South Africa Autoimmune Drugs Market by Product
9.4.5.1.2 South Africa Autoimmune Drugs Market by Application
9.4.5.2 Saudi Arabia Autoimmune Drugs Market
9.4.5.2.1 Saudi Arabia Autoimmune Drugs Market by Product
9.4.5.2.2 Saudi Arabia Autoimmune Drugs Market by Application
9.4.5.3 U.A.E Autoimmune Drugs Market
9.4.5.3.1 U.A.E Autoimmune Drugs Market by Product
9.4.5.3.2 U.A.E Autoimmune Drugs Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Autoimmune Drugs Market Overview
9.5.2 South and Central America Autoimmune Drugs Market Forecasts and Analysis
9.5.3 South and Central America Autoimmune Drugs Market Forecasts and Analysis - By Product
9.5.4 South and Central America Autoimmune Drugs Market Forecasts and Analysis - By Application
9.5.5 South and Central America Autoimmune Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Autoimmune Drugs Market
9.5.5.1.1 Brazil Autoimmune Drugs Market by Product
9.5.5.1.2 Brazil Autoimmune Drugs Market by Application
9.5.5.2 Argentina Autoimmune Drugs Market
9.5.5.2.1 Argentina Autoimmune Drugs Market by Product
9.5.5.2.2 Argentina Autoimmune Drugs Market by Application
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. AUTOIMMUNE DRUGS MARKET, KEY COMPANY PROFILES
11.1. - ABBOTT LABORATORIES, ACTIVE BIOTECH, ASTRAZENECA, GLAXOSMITHKLINE
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. JOHNSON AND JOHNSON LTD
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. LUPIN LIMITED
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ELI LILLY AND COMPANY
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. ZYDUS
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. BRISTOL-MYERS SQUIBB
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. AUTOIMMUNE INC
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
- Abbott Laboratories
- Active Biotech
- AstraZeneca
- GlaxoSmithKline
- Johnson & Johnson Ltd
- Lupin Limited
- Eli Lilly and Company
- Zydus
- Bristol-Myers Squibb
- AutoImmune Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For